It's the American PBMs that make their money on the difference between the list price and the price they sell it for. Higher list price means more profit
This was repeated over and over in the hearing. And apparently the regulation of PBMs (changed about a year ago) hasn't resulted in PBMs taking up cheaper drugs
You mean the difference between wholesale price of the manufacturer and the negotiated discount by the PBM right? Your use of pronouns obfuscates who you're talking about.
PulseView shouldn't be crashing a lot at all, honestly. Were you running the nightly or the 0.4.2 release? The 0.4.2 release is rather outdated, I'm working on making a new release soon to fix that.
The code generation has been pretty good upstream for many years now. It's easy enough
The hardest part of adding full support for RISC-V is to support the hardware floating point ABI. It's incredibly complicated for likely no real world reason. It will likely require a ton of code still to make freepascal fully compliant
The software and ABI ecosystem of RISC-V is what made me personally lose my love for it. The ISA is great
It's that structs of two simple fields need to be passed in registers. And more specifically that this rule is relevant for mixed integer and floating point fields.
It's a very specific rule that requires a ton of code to implement compared to the integer calling convention. And again like the weird AMD64 convention likely invented to squeeze out a theoretical few cycles that never occur outside microbenchmarks
This was repeated over and over in the hearing. And apparently the regulation of PBMs (changed about a year ago) hasn't resulted in PBMs taking up cheaper drugs
reply